Challenges in Describing Tremor and Dystonia
Aasef G Shaikh1,2,3,4, Alfonso Fasano5,6,7, Sanjay Pandey8
1Department of Neurology, Case Western University School of Medicine.
Neurology
|December 26, 2024
Summary
Experts recommend distinguishing between tremor and dystonia, recommending separate descriptive terms for coexisting conditions. This aims to clarify terminology for better clinical understanding and diagnosis of these movement disorders.
Area of Science:
- Neurology
- Movement Disorders
Background:
- Tremor is defined as rhythmic, oscillatory movement, while dystonia involves sustained or intermittent abnormal postures and repetitive movements.
- Tremor and dystonia frequently coexist, sometimes in the same body region, complicating clinical description and terminology.
- Existing terms like 'dystonic tremor' have been applied inconsistently, leading to confusion in the literature.
Purpose of the Study:
- To review and clarify the terminology used for coexisting tremor and dystonia.
- To develop recommendations for a more consistent and clinically useful approach to describing these movement disorders.
- To differentiate between rhythmic tremor and arrhythmic dystonic movements.
Main Methods:
- Convened a group of specialists to review existing terminology and clinical observations.
- Discussed the phenomenology of tremor and dystonia and their various combinations.
- Formulated recommendations for standardized terminology.
Main Results:
- Agreed that 'tremor' should exclusively describe rhythmic movements.
- Recommended against using tremor-related terms for grossly arrhythmic dystonic movements.
- Advocated for separate descriptive terms for coexisting tremor and dystonia, rather than hybrid terms.
Conclusions:
- A consistent terminology is essential for clear clinical communication regarding tremor and dystonia.
- Distinguishing between rhythmic tremor and arrhythmic dystonic movements is crucial.
- Future research may utilize motion analysis or physiologic measures to aid in clinical discrimination.
Related Concept Videos
Muscle Stimulation Frequency
1.9K
The contraction strength of muscles is regulated by motor neurons, which modulate the frequency of action potentials dispatched to the motor units based on the body's requirements. This process of varying the muscle stimulation frequency allows muscles to contract with a force that is precisely tailored to the needs of the moment, whether lifting a feather or a heavy box.
Wave summation
At low firing rates, motor neurons induce individual twitch contractions in muscle fibers. These twitches...
Wave summation
At low firing rates, motor neurons induce individual twitch contractions in muscle fibers. These twitches...
1.9K
Disorders of the Skeletal Muscle
826
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
826
Motor Unit Stimulation
1.2K
When the neuron of a motor unit fires an action potential, it triggers a series of events, leading to a twitch contraction in the muscle fibers. The process of excitation-contraction coupling is crucial in relaying the action potential to the muscle fibers.
The latent period of contraction marks the onset of excitation-contraction coupling, when the action potential propagates across the sarcolemma, preparing the muscle fibers for contraction. As the fibers enter the contraction phase, the...
The latent period of contraction marks the onset of excitation-contraction coupling, when the action potential propagates across the sarcolemma, preparing the muscle fibers for contraction. As the fibers enter the contraction phase, the...
1.2K
Parkinson's Disease: Treatment
148
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
148
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
617
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
617
Parkinson's Disease: Overview
306
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
306


